Interferon-γ in the Management of Infectious Diseases

  1. John I. Gallin;
  2. Joshua M. Farber;
  3. Steven M. Holland; and
  4. Thomas B. Nutman
  1. An edited summary of a Combined Clinical Staff Conference held 30 March 1994 at the National Institutes of Health, Bethesda, Maryland. Authors who wish to cite a section of the conference and specifically indicate its author may use this example for the form of reference: Farber JM. Mechanisms of action, pp 216-219. In: Gallin JI, moderator. Interferon-γ in the management of infectious diseases. Ann Intern Med. 1995; 123:216-224. Requests for Reprints: John I. Gallin, MD, Warren G. Magnuson Clinical Center, National Institutes of Health, Building 10, Room 2C146, 10 Center Drive, MSC 1504, Bethesda, MD 20892-1504.

    Abstract

    Interferon-γ has pleiotropic adjuvant effects on host defenses. These effects have made interferon-γ particularly useful for enhancing host defenses in patients with chronic granulomatous disease of childhood and thus for reducing the incidence of life-threatening infections in these patients. Increasingly, data suggest that interferon-γ will be useful for treating infections characterized by intracellular persistence in macrophages, such as toxoplasmosis, leishmaniasis, and mycobacteriosis. Interferon-γ is emerging as an important cytokine for use in the treatment of infectious diseases.

    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med August 1, 1995 vol. 123 no. 3 216-224
    1. » Abstract
    2. Figures
    3. Full Text
    4. Full Text (PDF)

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 17, 2009, 151 (10)
    1. Alert me to current issues